Vantage logo

Fibrocell gets a reality check

Promising data with Fibrocell’s epidermolysis bullosa gene therapy send the company down as funding worries kick in.

Vantage logo

The bubble bursts for Proteostasis

Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.